SmartTRAK spotlights OSSIO in an interview at AANA 2025 in Washington, DC. 

Bryan Jones, vice president of marketing and medical education at OSSIO, discusses the company’s novel bio-integrative OSSIOfiber implants in an interview with SmartTRAK at the Arthroscopy Association of North America (AANA) 2025 Meeting in Washington DC. 

Watch the following video to learn more about OSSIO and its novel technology. (17:50 min.) A link to download a complete transcript of the interview is also provided below. 

Hey everybody, it's Andy Knapik, senior analyst with SmartTRAK covering sports medicine arthroscopy. I'm here at the AANA meeting in Washington, DC, and right now I'm joined by Bryan Jones, an old friend of mine who is now what, VP of marketing, right?

Bryan Jones: Yes.

For OSSIO. And OSSIO is really this great up-and-coming company. We've profiled them in the past, and I think their products are really incredible and the things that they're doing are really amazing. When you first joined OSSIO you came to me and said ‘Hey, you need to come check this out. This stuff's really cool.’ So I went and looked at it and the first thing I see is these kind of bioabsorbable pins, which 25 years ago I started my career by selling Bionix, which is absorbable pins and screws and stuff. Back then you could bend the pins. They were never all that sturdy. So, when you first talked to me about this I was a little dubious, and then I put my hands on one and you couldn't bend it, couldn't bend it at all. And I thought ‘Well, that's really interesting.’ And then you guys came out with a compression staple, which is completely amazing.

BJ: Yeah, right.

The only one on the market, right?

BJ: Only one in the world. Yes, the only non-permanent compression staple ever.

So talk to me about just about OSSIO, about the product. What makes OSSIO products as good as they are?

BJ: Yes. I'll touch on where you started when you said you and I first met probably what, six years ago now? And your initial reaction is probably like 10,000 other reactions that we got back then. The hardest thing we ever had to do was convince people that this was not a typical biocomposite or bioabsorbable implant. That was the hardest hurdle. To do that, we had to really tell them about ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with Bryan Jones, Ossio's VP of Marketing & Medical Education, conducted by  Andy Knapik, SmartTRAK Senior Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies.

SmartTRAK spotlights Pristine Surgical in an interview at AANA 2025 in Washington, DC. 

Bryan Lord, CEO of Pristine Surgical, discussed the company’s Summit 4K, single-use arthroscopic camera in an interview with SmartTRAK at the Arthroscopy Association of North America (AANA) 2025 Meeting in Washington, D.C . 

Watch the following video to learn more about Pristine Surgical and its novel technology. (21:27 min.) A link to download a complete transcript of the interview is also provided below. 

Hey, everybody, it's Andy Knapik, Senior Analyst for SmartTRAK for all things sports medicine and arthroscopy. I'm here at the AANA meeting in Washington, D.C. We're at the Pristine Surgical booth. I'm joined by Bryan Lord, CEO of Pristine Surgical, and here just to talk about what they have going on. They have a single-use arthroscopic camera.

Bryan, I've known you now for probably a few years, we've talked about this quite a bit. When we look in the video capital world, we see a lot of different things going on right now. We have traditional capital systems like the Strykers, and Smith+Nephews, Arthrexes of the world, with a full tower. We have some wireless options out there now that are pretty intriguing. And then we have some single-use options. Arthrex has a nanoscope and then you guys have yours as well.

So, talk about how this got started, what benefits you initially saw, and how is that progressing now.

BL: Yes, so the genesis of the scope that we see here today actually was in a rather niche application. Some docs said, ‘Look, we think we could do some things different in visualization.’ And they were looking for ways to do some different angular types of views, 30, 70, in more of a pannable configuration. The early days of the development we did in partnership with a group called DECA Research in Manchester, New Hampshire, led by the noted medtech developer and entrepreneur engineer, Dean Kamen. In the conversation with those doctors and Dean, the concept came up (Dean's idea) to say, ‘Look, we think that we could do this single use. Would that be interesting?’

At that time, it was still early in the ways that people were understanding the proliferation of digital technologies, but everybody knew, including Dean, who's always been in the forefront, this was really a big idea. How could we take today's burgeoning areas of digital photography and bring that into the surgical suite? And it was early on that we knew that it was ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with Bryan Lord, CEO of Pristine Surgical, conducted by  Andy Knapik, SmartTRAK Senior Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies.

SmartTRAK spotlights Tetrous in an interview at AAOS 2025 in San Diego. 

Andy Carter, Chief Technology Officer and Founder of Tetrous, discusses the company’s novel approach to addressing Enthesis Failure Syndrome in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego. 

To learn more about Tetrous and its novel technology, listen to the following video. (21:42 min.) A link to download the transcript of the interview is also provided below. 

Hey everybody, it's Andy Knapik, live here at AAOS 2025 in San Diego. Today I'm joined here with a friend, colleague, and someone I've known now for, I guess a couple years, Andy Carter, Founder, Chief Technology Officer of a company called Tetrous, which is really some exciting biologic technology. So I just brought him along. We're going to chat a little bit about it. So Andy, why don't you just tell everybody what it is about Tetrous and what you guys do and why it's so great.

Andy Carter: Thanks for the opportunity. It's a great topic to talk about and I really, really love it. So we started Tetrous a couple of years ago. We spun it out of Theracell, the company that we sold to, ISTO Biologics. They're doing great and taking the technology in the spine and doing various things. But along the way, I read quite a few papers about how demineralized bone matrix materials could influence enthesis repair. And that's getting back to sports medicine, which is my roots and well, my real passion. I looked at these papers and they basically showed that demineralized bone matrix materials could influence the enthesis to heal. A tendon, the enthesis, is the bit between the tendon and the bone. It's the junction. It's how you get load transfer between rigid bone and flexible tendon. It's a biological structure that's very exquisite and unique. You look at the histology and the biologists go into raptures and "wows" about it and whatever.

The fundamentals are that you've got collagen fibers going from the bone through into the tendon. That's what gives you the strength. You see them in the histology with Sharpey's fibers. If you just reattach tendon to bone, you just get scar tissue. Scar tissue is not as strong. Basically, it pulls out and thins and fails with time. So part of the reason that we see so many problems with rotator cuff repair is that nobody's doing anything to heal the enthesis. There was this literature out there saying, ‘Hey, you can use DBM for this,’ but none of the papers showed it in any way that was something that you could see a surgeon being able to use-

Right, a practical form.

AC: There's one group, guys I know very well had used DBM powder. Now DBM powder, you can do it in a rat study and show that it works, but that's not a product. So what we were able to do, one of the clever things about the technology that we developed at Theracell, the fiber technology is, it allows us to ....

Click the button below to download and read the complete transcript of SmartTRAK's interview with Andy Carter, founder and CTO of Tetrous, conducted by Andy Knapik, SmartTRAK Senior Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies.

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

SmartTRAK highlights the key trends in the US Arthroscopic Technologies Market that will drive growth in 2025 and beyond.

The Arthroscopic Technologies (AT) Market is poised for significant advancements as we move through 2025 and beyond. With an anticipated compound annual growth rate (CAGR) of 4.3%, the US AT market is projected to rapidly expand by 2028. This growth is driven by technological innovations and the increasing prevalence of minimally invasive procedures.

In this downloadable market outlook article, SmartTRAK highlights the top technology trends to watch in 2025 that are shaping the future of AT, including:

• Continued Evolution in Arthroscopic Visualization
  • The arthroscopic visualization segment is undergoing a transformation driven by technological advancements and shifting market dynamics, increasing at ... (read more)
• Growth in Bundled Solutions
  • In the AT space, consumables such as resection tools, radiofrequency (RF) devices and fluid management products are significant revenue drivers. SmartTRAK estimates ... (read more)
• ASC Shift Driving Demand for All-in-One Solutions
  • The growth of ASCs has heightened the demand for all-in-one solutions, enabling sports medicine companies to ... (read more)
• Growing Interest in Direct Display Communications
  • SmartTRAK expects to see growing interest in direct display communications in 2025. Building on these advancements in integrated arthroscopic visualization, the next frontier is  ... (read more)
• Challenges and Future Outlook
  • While advancements in arthroscopic technologies are progressing, they remain ... (read more)

Want to stay ahead of the curve in arthroscopic technologies for 2025 and beyond? Click the button below to download Andy Knapik's market outlook article, "The Future of Arthroscopic Technologies in 2025 and Beyond." As SmartTRAK’s Sr Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies, Andy provides an informative analysis of the latest market shifts, including the challenges ahead for the industry.

Dr. Chris Jeffery, founder and CEO of Convergence Medical, discusses the V01, the world's first arthroscopic surgical robot.

In a recent interview with SmartTRAK, Dr. Chris Jeffery, the founder and CEO of Convergence Medical, discussed the V01, the world’s first dedicated arthroscopic surgical robot. In the interview, Dr. Jeffery shared insights into the V01’s novel design, business model, and technological advancements that position it as the next evolution in arthroscopic innovation. The V01 received FDA breakthrough designation in 2023 and is on track for FDA clearance and a US launch in late 2025.

Click on the following video to watch the interview (59:11 min). A complete transcript of the interview is available here. For more details, interview topics by timecode are provided below.

Interview Topics By Timecode:

• 00:50 Dr Jeffery’s background.
• 10:00 V01 overview.
• 20:25 Performing a repair with the V01.
• 26:50 V01 cost.
• 36:10 Surgeon feedback.
• 40:10 Importance of an arthroscopy-specific robot.
• 42:40 Novel design of the V01.
• 44:45 Commercial path.

Click the button below to download a complete transcript of SmartTRAK's interview with Dr. Chris Jeffrey, CEO of Convergence Medical Sciences, conducted by Andy Knapik, Senior Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies.

SmartTRAK highlights key trends and happenings in sports medicine and arthroscopy at AAOS 2024.

The American Academy of Orthopaedic Surgeons (AAOS) convened this year in San Francisco, California, from February 12-16. Following several years of subdued participation due to the COVID-19 pandemic, last year's strong showing at AAOS in Las Vegas fostered expectations for a continuation of momentum this year. Despite lower-than-projected attendance from medical professionals, the event featured a robust presence of large and small companies presenting their products and services. So, what was the buzz at the meeting?

In this Perspective article, which can be downloaded here, SmartTRAK highlights key takeaways from AAOS for companies competing in the Sports Medicine Market, including the following topics:

• Continued Interest in Biologic-driven Soft Tissue Fixation
  Companies are still helping drive soft tissue fixation sales through the use of biologics, which now are key advancements in technology at the forefront of sports medicine surgical procedures. Smith+Nephew continues to drive its Sports Medicine business with ... (read more)
  
  
• Ongoing Focus on the ASC Market
  Companies at AAOS had a prominent focus on the Ambulatory Surgery Center (ASC) Market. According to the SmartTRAK US Ortho ASC Market Overview, as of 2022, there were over ... (read more)
  
  
• Developments in Arthroscopic Technologies
  Another common theme on display across the AAOS 2024 exhibit floor was the showcasing of surgical video technologies. All the big players in sports medicine had their video systems on display, and some notable systems stood out. Stryker highlighted its newest ... (read more)

To download and read the complete "Highlights in Sports Medicine and Arthroscopy from AAOS 2024" Perspective article by Andy Knapik, SmartTRAK Senior Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies, just click the button below.

Orahn Preiss-Bloom, founder and Chief Innovation Officer of Ossio Ltd. discusses Osssio’s advancements in innovations in the world of bio-integrative fixation devices.

In an interview with SmartTRAK, Orahn Preiss-Bloom, the founder and Chief Innovation Officer of Ossio Ltd, discusses how Ossio came to be, what makes their products different and where he sees the Company going in the future.

To find out more about Ossio, click on the following video to watch the interview (24:42 min). To download a complete transcript of the interview, click here. For more details, interview topics by timecode are provided below.

Interview Topics By Timecode

00:44 Orahn’s background in the medical industry.
03:53 What differentiates the OSSIO product.
07:55 Initial uses for OSSIOfiber.
12:40 Overcoming surgeon objections to biointegrative materials.
15:13 Ossio education labs.
19:44 Ossio in sports medicine.
22:41 Surgeon concerns.

To download the complete transcript of the interview with Orahn Preiss-Bloom, Founder and Chief Innovation Officer of Ossio Ltd, just click the button below.